IShares Biotechnology Valuation
| IBB Etf | USD 132.65 0.31 0.23% |
At this time, the entity appears to be overvalued. iShares Biotechnology ETF retains a regular Real Value of $118.72 per share. The prevalent price of the entity is $132.65. Our model calculates the value of iShares Biotechnology ETF from evaluating the entity fundamentals such as Number Of Employees of 9, price to book of 3.39 X, and Price To Earning of 3.16 X as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that IShares Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of iShares Biotechnology ETF is based on 3 months time horizon. Increasing IShares Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since IShares Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IShares Etf. However, IShares Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 132.65 | Real 118.72 | Hype 132.8 |
The real value of IShares Etf, also known as its intrinsic value, is the underlying worth of iShares Biotechnology ETF ETF, which is reflected in its stock price. It is based on IShares Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of IShares Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of iShares Biotechnology ETF helps investors to forecast how IShares etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IShares Biotechnology more accurately as focusing exclusively on IShares Biotechnology's fundamentals will not take into account other important factors: IShares Biotechnology Total Value Analysis
iShares Biotechnology ETF is currently forecasted to have company total value of 9.22 B with market capitalization of 9.22 B, debt of , and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the IShares Biotechnology fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.22 B | 9.22 B |
IShares Biotechnology Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of IShares suggests not a very effective usage of assets in January.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates IShares Biotechnology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in IShares Biotechnology and how it compares across the competition.
About IShares Biotechnology Valuation
The etf valuation mechanism determines IShares Biotechnology's current worth on a weekly basis. Our valuation model uses a comparative analysis of IShares Biotechnology. We calculate exposure to IShares Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IShares Biotechnology's related companies.The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Biotechnology ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.